<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668434</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR053960</org_study_id>
    <secondary_id>R01AR053960</secondary_id>
    <nct_id>NCT00668434</nct_id>
  </id_info>
  <brief_title>Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica</brief_title>
  <acronym>ACT FAST</acronym>
  <official_title>A Corticosteroid Taper for Acute Sciatica Treatment (The ACT FAST Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sciatica is a condition that causes a sharp, burning pain in the back, buttock, and leg. The
      condition is caused by injury to or compression of the sciatic nerve, which is located in the
      back of the leg. This study will determine the effectiveness of the steroid prednisone in
      decreasing pain and improving function in people with sciatica.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sciatica is most often caused by a herniated disc in the lumbar region of the back and
      results from inflammation of the nerve roots as they exit the spine. It is a very common
      cause of back and leg pain, loss of function, and inability to work. Although sciatica is
      common, the effectiveness of current treatments is limited. Epidural steroid injections
      (ESIs), which can reduce inflammation of the nerve roots, are commonly used to decrease
      sciatica pain and restore normal function in patients. The exact effectiveness of ESIs,
      however, is unknown. If inflammation, and not compression, is the main cause of sciatica, it
      is reasonable to consider giving the steroid orally rather than by injection. If oral
      steroids prove effective, patients and clinicians will have access to a simple, inexpensive
      therapy that can be prescribed by primary care physicians without delay. This study will
      determine the effectiveness of the oral steroid prednisone in decreasing pain and improving
      function in people with sciatica.

      Participants in this study will attend a screening visit at which they will answer questions
      about their health to determine eligibility, undergo a neurologic exam, and have a plain
      lower spine x-ray. An MRI of the lower spine will be performed for those who meet clinical
      eligibility. Participants whose MRI shows that a disc has ruptured in a specific way will be
      randomly assigned to receive either a 15-day course of prednisone capsules or a 15-day course
      of placebo capsules. Participants will take their assigned study medications in addition to
      their usual pain medications.

      At Week 3, participants will return for a follow-up visit during which they will answer
      questions about their pain and general health and wellness. Participants who are still having
      considerable pain will be offered an epidural steroid injection (ESI) as a part of the study.
      At Week 6, participants will be called at home for a telephone interview and again answer
      questions about their general health and wellness; this telephone call will last about 20
      minutes. If they continue to have considerable pain, they will be offered a second ESI as
      part of the study.

      At Week 12, an interviewer will phone participants to determine if their pain has decreased
      and whether they have been able to return to their normal activities. The telephone contact
      will last about 20 minutes. Additional information about their back problems will be obtained
      from their medical records and from Kaiser Permanente's computerized medical records on their
      use of health care and medicines for back problems. At Week 24, participants will attend an
      evaluation visit at the Spine Clinic to assess their progress and symptoms. At Week 52 (1
      year from randomization), participants will undergo a final telephone interview.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oswestry Disability Index, v2</measure>
    <time_frame>Baseline, Week 3 follow-up</time_frame>
    <description>The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Numerical Rating Scale</measure>
    <time_frame>Baseline, Week 3 follow-up</time_frame>
    <description>Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index, v2</measure>
    <time_frame>Baseline, Week 52 follow-up</time_frame>
    <description>The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Numerical Rating Scale</measure>
    <time_frame>Baseline, Week 52 follow-up</time_frame>
    <description>Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 15-day tapering course of prednisone capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a 15-day course of placebo capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seeks care at a Kaiser Permanente clinic spine care specialist at the San Jose,
             Redwood City, or Roseville site

          -  Complains of low back pain and functionally incapacitating leg pain extending below
             the knee with a nerve root distribution

          -  Score of at least 20 on the modified Oswestry Disability Index

          -  Appears, in the opinion of the study physician, to be very likely to have a herniated
             lumbar disc

          -  MRI study confirms a herniated disc consistent with the signs and symptoms

        Exclusion Criteria:

          -  Onset of sciatica symptoms occurred more than 3 months before study entry

          -  Cauda equina syndrome

          -  Active cancer

          -  Acute spinal fracture

          -  Currently taking oral steroids

          -  Diabetes mellitus and taking insulin or glycohemoglobin greater than 10%

          -  Systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater
             than 110 mm Hg

          -  Pregnant or breastfeeding

          -  Active peptic ulcer disease

          -  History of intolerance to steroid therapy

          -  Bleeding diathesis or anticoagulant therapy

          -  Ongoing litigation or workers compensation claim for low back pain or sciatica

          -  Underwent previous lumbar surgery

          -  Received epidural steroid injection (ESI) within the 12 months before study entry

          -  Unable to read or speak English

          -  Progressive or severe motor loss
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harley Goldberg, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente San Jose Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew L. Avins, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente Division of Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Firtch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente Redwood City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Tyburski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente, Roseville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California, Redwood City</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California, San Jose</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>94119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <results_first_submitted>October 20, 2014</results_first_submitted>
  <results_first_submitted_qc>April 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2015</results_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Back Pain</keyword>
  <keyword>Leg Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prednisone</title>
          <description>Participants will receive a 15-day tapering course of prednisone capsules.
Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive a 15-day course of placebo capsules.
Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Outcome Time Point (3 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="181">Baseline</participants>
                <participants group_id="P2" count="88">Baseline</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Secondary Outcome Time Point (52 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179">Baseline</participants>
                <participants group_id="P2" count="88">Baseline</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prednisone</title>
          <description>Participants will receive a 15-day tapering course of prednisone capsules.
Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive a 15-day course of placebo capsules.
Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="11.8"/>
                    <measurement group_id="B2" value="46.7" spread="12.6"/>
                    <measurement group_id="B3" value="46.0" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oswestry Disability Index, v2</title>
        <description>The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.</description>
        <time_frame>Baseline, Week 3 follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisone</title>
            <description>Participants will receive a 15-day tapering course of prednisone capsules.
Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a 15-day course of placebo capsules.
Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Oswestry Disability Index, v2</title>
          <description>The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" spread="1.4"/>
                    <measurement group_id="O2" value="-13.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Numerical Rating Scale</title>
        <description>Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.</description>
        <time_frame>Baseline, Week 3 follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisone</title>
            <description>Participants will receive a 15-day tapering course of prednisone capsules.
Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a 15-day course of placebo capsules.
Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Numerical Rating Scale</title>
          <description>Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="0.2"/>
                    <measurement group_id="O2" value="-2.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oswestry Disability Index, v2</title>
        <description>The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.</description>
        <time_frame>Baseline, Week 52 follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisone</title>
            <description>Participants will receive a 15-day tapering course of prednisone capsules.
Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a 15-day course of placebo capsules.
Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Oswestry Disability Index, v2</title>
          <description>The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.8" spread="1.5"/>
                    <measurement group_id="O2" value="-30.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Numerical Rating Scale</title>
        <description>Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.</description>
        <time_frame>Baseline, Week 52 follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisone</title>
            <description>Participants will receive a 15-day tapering course of prednisone capsules.
Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a 15-day course of placebo capsules.
Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Numerical Rating Scale</title>
          <description>Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="0.2"/>
                    <measurement group_id="O2" value="-4.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire study period, up to 52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prednisone</title>
          <description>Participants will receive a 15-day tapering course of prednisone capsules.
Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive a 15-day course of placebo capsules.
Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper GI bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Partial nephrectomy</sub_title>
                <description>Resection of renal cell carcinoma found incidentally on study imaging</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular problem</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear or eye disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal problem</sub_title>
                <counts group_id="E1" events="85" subjects_affected="41" subjects_at_risk="181"/>
                <counts group_id="E2" events="32" subjects_affected="8" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="45" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E2" events="29" subjects_affected="11" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic problem</sub_title>
                <counts group_id="E1" events="62" subjects_affected="17" subjects_at_risk="181"/>
                <counts group_id="E2" events="34" subjects_affected="14" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorder</sub_title>
                <counts group_id="E1" events="78" subjects_affected="47" subjects_at_risk="181"/>
                <counts group_id="E2" events="36" subjects_affected="15" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary problem</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Kidney problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary problem</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic problem</sub_title>
                <counts group_id="E1" events="56" subjects_affected="18" subjects_at_risk="181"/>
                <counts group_id="E2" events="27" subjects_affected="10" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew Avins</name_or_title>
      <organization>Kaiser Permanente, Northern California</organization>
      <phone>510-891-3557</phone>
      <email>andy.l.avins@kp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

